We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

IRAK

IRAK inhibitors act on interleukin-1 receptor-associated kinases (IRAKs), kinases of innate immune receptor signaling. IRAK was cloned in 1996 as a serine/threonine kinase that associates with the interleukin-1 (IL-1) receptor after stimulation. Mice lacking IRAK4 showed severe defects in IL-1 and Toll-like receptor signaling, which established a central role for this family member. The adaptor myeloid differentiation primary response 88 (MyD88) recruits IRAK4, which then phosphorylates IRAK1 on the route to nuclear factor kappa B activation. Emavusertib, listed as CA-4948, and IRAK inhibitor 4 target IRAK4, while IRAK-1-4 Inhibitor I blocks both IRAK1 and IRAK4. The list also contains compounds with other targets, such as the c-Jun N-terminal kinase inhibitor JNK-IN-7.

Items 26-29 of 29

  • PROTAC IRAK4 degrader-6
    Cat. No.
    A64948
    CAS No.
    2360530-72-7

    PROTAC IRAK4 degrader-6

    PROTAC IRAK4 Degrader-6 is a Cereblon-based PROTAC designed to selectively degrade interleukin-1 receptor-associated kinase 4 (IRAK4). This compound targets IRAK4 for ubiquitination and subsequent proteasomal degradation, effectively modulating inflammatory signaling pathways. It is utilized in research applications focused on understanding the role of IRAK4 in immune responses and developing novel therapeutic strategies for inflammatory diseases.

    View Details

    Out of stock

    All 3 sizes
  • Thalidomide-NH-C2-azaspiro[3.5]nonane hydrochloride
    Cat. No.
    A80259
    CAS No.
    2573304-92-2

    Thalidomide-NH-C2-azaspiro[3.5]nonane hydrochloride

    Thalidomide-NH-C2-azaspiro[3.5]nonane hydrochloride serves as a crucial intermediate in the synthesis of IRAK degraders. Its structural properties facilitate the development of compounds that modulate immune responses by targeting IRAK proteins. This reagent is valuable for researchers focusing on therapeutic applications in inflammatory diseases and immune regulation.

    View Details

    Out of stock

    All 3 sizes
  • PROTAC IRAK4 ligand-3
    Cat. No.
    A81321
    CAS No.
    2434848-46-9

    PROTAC IRAK4 ligand-3

    PROTAC IRAK4 ligand-3 is a PROTAC ligand that selectively targets IRAK4, an integral component of the Toll-like receptor signaling pathway. This compound facilitates the targeted degradation of IRAK4, thereby influencing key signaling cascades involved in inflammation and cancer. It is valuable for research applications focusing on cancer therapies and the modulation of inflammatory responses.

    View Details

    Out of stock

    All 3 sizes
  • PSP-0119
    Cat. No.
    B22084
    CAS No.
    3104855-98-0

    PSP-0119

    PSP-0119 is a highly selective PROTAC degrader targeting IRAK4, demonstrating an IC50 of 2.83 nM. This compound effectively inhibits IRAK4 kinase activity, NF-κB signaling, and IL-1β-induced IRAK4 phosphorylation. Notably, PSP-0119 induces degradation of IRAK4 specifically in FLT3-mutant acute myeloid leukemia (AML) cell lines while sparing FLT3-wild-type AML cells and normal bone marrow. It serves as a valuable tool for research into the mechanisms underlying AML, particularly in targeting aberrant IRAK4 activity.

    In stock View Details
    5 mg
    $1,230.00
    10 mg
    $1,890.00
    All 5 sizes

Items 26-29 of 29

Added to your cart

View Cart Checkout

    Loading...